
    
      A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and
      Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects with Type 2
      Diabetes Mellitus
    
  